Published in Am J Pathol on November 01, 2000
Previously unidentified changes in renal cell carcinoma gene expression identified by parametric analysis of microarray data. BMC Cancer (2003) 2.90
A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A (2003) 2.23
Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol (2000) 2.05
Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer (2013) 1.93
Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci U S A (2009) 1.59
Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2013) 1.40
Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev (2012) 1.31
Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol (2002) 1.24
Endothelin-1: a multifunctional molecule in cancer. Br J Cancer (2003) 1.23
Role of the endothelin axis and its antagonists in the treatment of cancer. Br J Pharmacol (2011) 1.21
Endothelin. Cell Mol Life Sci (2010) 1.10
Potential novel candidate polymorphisms identified in genome-wide association study for breast cancer susceptibility. Hum Genet (2011) 1.08
Endothelin receptors as novel targets in tumor therapy. J Transl Med (2004) 1.07
Endothelin receptor A blockade enhances taxane effects in prostate cancer. Neoplasia (2006) 1.07
Endothelin B receptor, a new target in cancer immune therapy. Clin Cancer Res (2009) 1.05
Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells. Cancer Biol Ther (2012) 1.04
Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. Br J Cancer (2005) 0.98
Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes. Cancer Res (2011) 0.97
Optical techniques for the molecular imaging of angiogenesis. Eur J Nucl Med Mol Imaging (2010) 0.94
BMP-9 induced endothelial cell tubule formation and inhibition of migration involves Smad1 driven endothelin-1 production. PLoS One (2012) 0.93
Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo. Am J Pathol (2003) 0.88
Endothelin-1 as a target for therapeutic intervention in prostate cancer. Invest New Drugs (2002) 0.86
Endothelin receptor blockade inhibits proliferation of Kaposi's sarcoma cells. Am J Pathol (2001) 0.86
Expression of endothelin-A-receptor predicts unfavourable response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer (2004) 0.85
Activated epidermal growth factor receptor in ovarian cancer. Cancer Treat Res (2009) 0.84
ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. Expert Opin Investig Drugs (2008) 0.81
The independent, unfavorable prognostic factors endothelin A receptor and chemokine receptor 4 have a close relationship in promoting the motility of nasopharyngeal carcinoma cells via the activation of AKT and MAPK pathways. J Transl Med (2013) 0.80
miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. Oncotarget (2016) 0.80
The endothelin-integrin axis is involved in macrophage-induced breast cancer cell chemotactic interactions with endothelial cells. J Biol Chem (2014) 0.79
Endothelin receptor B antagonists decrease glioma cell viability independently of their cognate receptor. BMC Cancer (2008) 0.78
Nuclear β-arrestin1 is a critical cofactor of hypoxia-inducible factor-1α signaling in endothelin-1-induced ovarian tumor progression. Oncotarget (2016) 0.78
Expression of endothelin 1 and its angiogenic role in meningiomas. Virchows Arch (2006) 0.77
Inhibitory effect of endothelin A receptor blockade on tumor growth and liver metastasis of a human gastric cancer cell line. Gastric Cancer (2007) 0.76
Endothelin-A receptor antagonists in prostate cancer treatment-a meta-analysis. Int J Clin Exp Med (2015) 0.76
Targeting the endothelin receptor in prostate cancer bone metastasis: Back to the mouse? Cancer Biol Ther (2010) 0.75
G-231A and G+70C Polymorphisms of Endothelin Receptor Type-A Gene could Affect the Psoriasis Area and Severity Index Score and Endothelin 1 Levels. Indian J Dermatol (2015) 0.75
Effects of silencing endothelin-1 on invasion and vascular formation in lung cancer. Oncol Lett (2017) 0.75
Endothelial follistatin-like-1 regulates the postnatal development of the pulmonary vasculature by modulating BMP/Smad signaling. Pulm Circ (2017) 0.75
Role of Lactoferrin in the Carcinogenesis of Triple-Negative Breast Cancer. J Cancer Clin Trials (2016) 0.75
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med (1991) 19.46
Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (1989) 16.71
Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (1983) 15.43
Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol (1995) 10.61
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science (1992) 7.49
Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev (1994) 4.19
Hypoxia induces endothelin gene expression and secretion in cultured human endothelium. J Clin Invest (1991) 3.18
How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res (1986) 2.69
Endothelins. N Engl J Med (1995) 2.52
Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst (1995) 2.44
Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene (1991) 2.39
Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer (1997) 2.20
Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol (2000) 2.05
Tumor angiogenesis in advanced stage ovarian carcinoma. Am J Pathol (1995) 2.02
Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer. Clin Cancer Res (1996) 2.00
Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol (1998) 1.90
Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res (1997) 1.85
Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res (1993) 1.71
Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res (1994) 1.59
Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest (1996) 1.50
Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res (1999) 1.46
The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin Cancer Res (1999) 1.43
Ovarian cancer biology. Semin Oncol (1991) 1.40
An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci U S A (1999) 1.37
Permissive role of nitric oxide in endothelin-induced migration of endothelial cells. J Biol Chem (1997) 1.34
Activation of mitogenic signaling by endothelin 1 in ovarian carcinoma cells. Cancer Res (1997) 1.34
Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res (1998) 1.26
Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J Biol Chem (1997) 1.23
Vascular endothelial growth factor (VEGF) expression and survival in human epithelial ovarian carcinomas. Cancer Lett (1997) 1.13
Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int J Cancer (1996) 1.11
Raised endothelin 1 levels in patients with colorectal liver metastases. Br J Surg (1998) 1.10
Endothelins as autocrine regulators of tumor cell growth. Trends Endocrinol Metab (1998) 1.10
Correlation of endothelin-1 and transforming growth factor beta 1 with malignancy and vascularity in human gliomas. J Neuropathol Exp Neurol (1997) 1.08
Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop. J Biol Chem (1994) 1.08
Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res (1995) 1.05
Co-operation between endothelin and nitric oxide in promoting endothelial cell migration and angiogenesis. Clin Exp Pharmacol Physiol (1999) 1.04
Proliferation and migration of endothelial cells is promoted by endothelins via activation of ETB receptors. Am J Physiol (1995) 0.99
Angiogenesis in cancer: the role of endothelin-1. Ann R Coll Surg Engl (1999) 0.96
VEGF, VEGFR-1, VEGFR-2, microvessel density and endothelial cell proliferation in tumours of the ovary. Int J Cancer (1999) 0.88
Localization and characterization of endothelin-1 receptor binding in the blood vessels of human pulmonary tumors. J Cardiovasc Pharmacol (1995) 0.87
Autoradiographic localization of brain receptors for peptide hormones: angiotensin II, corticotropin-releasing factor, and gonadotropin-releasing hormone. Methods Enzymol (1986) 0.86
Endothelin-3 mediated proliferation in wounded human umbilical vein endothelial cells. Biochem Biophys Res Commun (1993) 0.83
Expression of Ia-like antigens in normal human nonlymphoid tissues. Transplantation (1981) 2.29
Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene (2000) 2.08
Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol (2000) 2.05
The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer (1991) 1.95
A tumor-associated fibronectin isoform generated by alternative splicing of messenger RNA precursors. J Cell Biol (1989) 1.73
The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer (2000) 1.71
From the fetal liver to spleen and gut: the highway to natural antibody. Mucosal Immunol (2009) 1.59
Alpha 6 beta 4 and alpha 6 beta 1 integrins associate with ErbB-2 in human carcinoma cell lines. Exp Cell Res (1997) 1.58
Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. Br J Cancer (1993) 1.55
Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer (1981) 1.55
Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol (2001) 1.54
Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet (2001) 1.54
Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer (2000) 1.50
Expression of c-kit receptor in normal and transformed human nonlymphoid tissues. Cancer Res (1992) 1.47
Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res (1999) 1.46
Morphological, immunochemical, and biochemical study of rabbit achilles tendon at various ages. J Bone Joint Surg Am (1980) 1.43
Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res (1990) 1.43
Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res (1997) 1.42
[Radioimmuno-guided surgery (RIGS) in breast disease]. Chir Ital (2001) 1.39
Human papillomavirus in breast cancer. Breast Cancer Res Treat (1992) 1.38
Isolation and molecular cloning of a fast-growing strain of human hepatitis A virus from its double-stranded replicative form. J Virol (1985) 1.38
Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues. Int J Cancer (1990) 1.36
Endoglin is a suitable target for efficient imaging of solid tumors: in vivo evidence in a canine mammary carcinoma model. Clin Cancer Res (2000) 1.35
Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. Br J Cancer (1996) 1.35
Progression of human cutaneous melanoma is associated with loss of expression of c-kit proto-oncogene receptor. Int J Cancer (1992) 1.34
Activation of mitogenic signaling by endothelin 1 in ovarian carcinoma cells. Cancer Res (1997) 1.34
Comparative study of antibodies to native and denatured DNA. J Immunol (1970) 1.29
Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res (2001) 1.29
Experimental skin lesions in mice resembling systemic lupus erythematosus. Arthritis Rheum (1973) 1.27
Food-dependent exercise-induced anaphylaxis: clinical and laboratory findings in 54 subjects. Int Arch Allergy Immunol (2001) 1.27
Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res (1984) 1.26
Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res (1983) 1.25
Changes in expression of alpha 6/beta 4 integrin heterodimer in primary and metastatic breast cancer. Br J Cancer (1992) 1.24
Changes in Ia-like antigen expression on malignant human cells. Immunogenetics (1981) 1.22
Selective changes in expression of HLA class I polymorphic determinants in human solid tumors. Proc Natl Acad Sci U S A (1989) 1.20
Overexpression of the met/HGF receptor in renal cell carcinomas. Int J Cancer (1996) 1.18
Comparative analysis of the expression of the extracellular matrix protein tenascin in normal human fetal, adult and tumor tissues. Int J Cancer (1991) 1.16
Experimental renal disease induced by DNA-anti-DNA immune complexes. J Clin Invest (1972) 1.13
Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Res (1995) 1.13
Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res (2000) 1.13
Differential tissue distribution and ontogeny of DC-1 and HLA-DR antigens. Immunogenetics (1984) 1.12
Expression of HL-A antigens in synchronized cultures of human lymphocytes. J Immunol (1972) 1.12
Diagnostic and prognostic value of peritoneal immunocytology in gastric cancer. J Clin Oncol (1998) 1.10
β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling. Oncogene (2012) 1.10
Multicenter study of immunoscintigraphy with radiolabeled monoclonal antibodies in patients with melanoma. Cancer Res (1986) 1.08
Prognostic relevance of altered Fas (CD95)-system in human breast cancer. Int J Cancer (2000) 1.08
Integrin expression in cutaneous malignant melanoma: association of the alpha 3/beta 1 heterodimer with tumor progression. Int J Cancer (1993) 1.07
Distinctive features of the alpha 1-domain alpha helix of HLA-C heavy chains free of beta 2-microglobulin. Hum Immunol (1996) 1.06
Regeneration of rabbit calcaneal tendon: a morphological and immunochemical study. Cell Tissue Res (1978) 1.06
Breast cancer is associated with loss of the c-kit oncogene product. Int J Cancer (1992) 1.05
Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin Cancer Res (1995) 1.05
Whole-genome scan for quantitative trait loci associated with birth weight, gestation length and passive immune transfer in a Holstein x Jersey crossbred population. Anim Genet (2008) 1.04
Immediate allergic reactions to cephalosporins: cross-reactivity and selective responses. J Allergy Clin Immunol (2000) 1.04
Immune complex nephritis in Schistosoma mansoni-infected mice. Eur J Immunol (1976) 1.03
Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells. Lab Invest (1996) 1.03
The Italian multi-centre project on evaluation of MRI and other imaging modalities in early detection of breast cancer in subjects at high genetic risk. J Exp Clin Cancer Res (2002) 1.02
Analysis of protein-protein interactions involved in the activation of the Shc/Grb-2 pathway by the ErbB-2 kinase. Oncogene (1995) 1.02
Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40S to human melanoma cells. J Natl Cancer Inst (1981) 1.02
A 94,000-dalton glycoprotein expressed by human melanoma and carcinoma cells. J Natl Cancer Inst (1982) 1.02
Human papillomavirus in head and neck carcinomas: prevalence, physical status and relationship with clinical/pathological parameters. Anticancer Res (2000) 1.00
An ErbB-3 antibody, MP-RM-1, inhibits tumor growth by blocking ligand-dependent and independent activation of ErbB-3/Akt signaling. Oncogene (2011) 0.99
Cardiac adrenergic nerve function and microvascular dysfunction in patients with cardiac syndrome X. Heart (2009) 0.99
Distribution of laminin and collagen type-IV in benign and malignant lesions of melanocytic origin. Int J Cancer (1985) 0.99
Expression of VE (vascular endothelial)-cadherin and other endothelial-specific markers in haemangiomas. J Pathol (1995) 0.98
Immunochemical localization of contractile proteins in mammalian meiotic chromosomes. Cell Tissue Res (1980) 0.98
Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens. J Natl Cancer Inst (1984) 0.97
Antigenic heterogeneity of surgically removed primary and autologous metastatic human melanoma lesions. J Immunol (1983) 0.97
HLA-C heavy chains free of beta2-microglobulin: distribution in normal tissues and neoplastic lesions of non-lymphoid origin and interferon-gamma responsiveness. Tissue Antigens (1997) 0.97
A primary amelanotic melanoma of the vagina diagnosed by immunocytochemistry. Int J Gynaecol Obstet (1989) 0.97
Bovine papillomavirus E5 oncoprotein binds to the activated form of the platelet-derived growth factor beta receptor in naturally occurring bovine urinary bladder tumours. Oncogene (2006) 0.96